Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.19 USD | -3.71% | -1.70% | -0.95% |
Mar. 22 | Lyra Therapeutics Files $300 Million Mixed Shelf Offering | MT |
Mar. 21 | Lyra Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Financials (USD)
Sales 2024 * | 1.38M | Sales 2025 * | 782K | Capitalization | 310M |
---|---|---|---|---|---|
Net income 2024 * | -68M | Net income 2025 * | -82M | EV / Sales 2024 * | 225 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 397 x |
P/E ratio 2024 * |
-5.14
x | P/E ratio 2025 * |
-4.66
x | Employees | 88 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 77.47% |
Latest transcript on Lyra Therapeutics, Inc.
1 day | -3.71% | ||
1 week | -1.70% | ||
Current month | -16.56% | ||
1 month | -14.07% | ||
3 months | -0.19% | ||
6 months | +47.86% | ||
Current year | -0.95% |
Managers | Title | Age | Since |
---|---|---|---|
Maria Palasis
CEO | Chief Executive Officer | 59 | 14-12-31 |
Jason Cavalier
DFI | Director of Finance/CFO | 51 | 21-09-12 |
Richard Nieman
CTO | Chief Tech/Sci/R&D Officer | 61 | 22-07-10 |
Members of the board | Title | Age | Since |
---|---|---|---|
Harlan Waksal
CHM | Chairman | 71 | 22-02-15 |
W. Smith
BRD | Director/Board Member | 68 | 19-11-18 |
James Tobin
BRD | Director/Board Member | 79 | 22-03-06 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-19 | 5.19 | -3.71% | 233,963 |
24-04-18 | 5.39 | -0.28% | 387,833 |
24-04-17 | 5.405 | +0.09% | 299,203 |
24-04-16 | 5.4 | +2.47% | 244,109 |
24-04-15 | 5.27 | -0.19% | 240,217 |
Delayed Quote Nasdaq, April 19, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-0.95% | 322M | |
-1.42% | 41.35B | |
+42.15% | 40.38B | |
+1.97% | 39.05B | |
-14.19% | 26.67B | |
+1.82% | 24.07B | |
-24.55% | 18.36B | |
-4.07% | 11.68B | |
+21.36% | 11.6B | |
+8.20% | 11.15B |
- Stock Market
- Equities
- LYRA Stock